Shantou Institute of Ultrasonic Instrument
301602
Hubei Sinophorus Electronic Materials
688545
Pansoft
300996
4
Jiayu Holding
300117
5
Wuxi Taclink Optoelectronics Technology
688205
US Stock MarketDetailed Quotes
VCYT Veracyte
- 43.760
- +0.160+0.37%
Trading Jan 22 12:42 ET
3.39BMarket Cap-336.62P/E (TTM)
44.420High43.390Low166.60KVolume43.640Open43.600Pre Close7.31MTurnover0.22%Turnover RatioLossP/E (Static)77.50MShares46.00052wk High2.88P/B3.38BFloat Cap18.61052wk Low--Dividend TTM77.18MShs Float86.030Historical High--Div YieldTTM2.36%Amplitude4.210Historical Low43.899Avg Price1Lot Size
About Veracyte Company
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Company Profile
SymbolVCYT
Company NameVeracyte
Listing DateOct 30, 2013
Issue Price13.00
Founded2006
CEOMr. Marc A. Stapley
MarketNASDAQ
Employees815
Fiscal Year Ends12-31
Address6000 Shoreline Court,Suite 300
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-243-6300
Websitehttp://www.veracyte.com
Company Executives
- Name
- Position
- Salary
- Marc A. Stapley
- Chief Executive Officer and Director
- 7.18M
- Annie McGuire
- General Counsel and Chief People Officer
- 2.48M
- Dr. John Leite
- Chief Commercial Officer, CLIA
- 1.92M
- Dr. Phillip G. Febbo, M.D.
- Chief Scientific and Chief Medical Officer
- 3.79M
- Jonathan Wygant
- Chief Accounting Officer
- --
- Rebecca Chambers
- Chief Financial Officer
- 2.78M
- Dr. Robert S. Epstein, M.D.,M.S.
- Chairman of the Board
- 337.98K
- Dr. Tom Miller, PhD
- Director
- --
- Brent Shafer
- Director
- --
- Evan Jones
- Independent Director
- 314.98K
- Jens Holstein
- Independent Director
- 327.47K
- Dr. Eliav Barr, M.D.
- Independent Director
- 294.98K
- Muna Bhanji, Ph.
- Independent Director
- 299.98K
- Karin Eastham
- Independent Director
- 314.98K
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day